Everolimus not checked
Novartis Pharmaceuticals · RAD001
FollowEvery change as it happens, and a Monday email
Trials
19 active
39 in total · 23 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA class
- Tested for
- Tuberous Sclerosis Complex
- Main trialPhase 3
- “The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3”In the company’s words, NCT02962414 on ClinicalTrials.gov
- Other names
- RAD001 · Afinitor
Other drugs for Tuberous Sclerosis Complex
- YCJ-01 Full Spectrum cannbis ExtractOils4Cure · Phase 3
- SVG103Sovargen · Phase 1/2
- AV078Aeovian Pharmaceuticals, Inc. · Phase 2
- RadiprodilGRIN Therapeutics, Inc. · Phase 1/2
- Sapu003SAPU NANO (US) LLC · Phase 1
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- SVG101Sovargen · NCT05490095 · finished
Coming up1
- 26 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2026-12-30 to 2027-02-26 · ClinicalTrials.gov NCT02962414
Trials39
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Feb 2027 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | |
| Phase 4Completed | 28 Aug 2020 | Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. | |
| Phase 4Completed | 25 Sep 2020 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | |
| Phase 4Completed | 18 Dec 2023 | Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus | |
| Phase 4Completed | 22 Feb 2024 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | |
| Phase 4Completed | 13 Oct 2026 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | |
| Phase 3Completed | 28 Nov 2014 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | |
| Phase 2Completed | 20 Apr 2012 | Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy | |
| Phase 2Completed | 20 Nov 2012 | Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Completed | 17 Dec 2015 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | |
| Phase 2Completed | 2 Jul 2018 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | |
| Phase 2Completed | 10 Feb 2020 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial | |
| Phase 2Completed | 25 Apr 2022 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | |
| Phase 1/2Completed | 3 Sep 2008 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | |
| Phase 1/2Completed | 25 Feb 2020 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. | |
| Phase 1Completed | 14 Mar 2018 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | |
| Phase 1Completed | 22 Feb 2022 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | |
| Phase 1Terminated | 13 Feb 2026 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | |
| Phase 3Authorised | not given | Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus. The LEVEL trial | |
| Phase 3/4Ended | not given | Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients | |
| Phase 2Authorised | not given | Individualized everolimus therapy in metastatic breast cancer | |
| Phase 3Authorised | not given | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 | |
| Phase 2Ended | not given | Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study. | |
| Phase 2Authorised | not given | Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical trial | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 2Authorised | not given | Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE) | |
| Phase 2Authorised | not given | An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer | |
| Phase 3Authorised | not given | A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study- | |
| Phase 4Authorised | not given | Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR) | |
| Phase 1/2Authorised | not given | AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | |
| Phase 3Authorised | not given | UNIRAD : Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease | |
| Phase 4Ended | not given | The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. | |
| Phase 2Authorised | not given | A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL | |
| Phase 4Authorised | not given | Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation | |
| Phase 2Authorised | not given | Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE) | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG | |
| Phase 1Authorised | not given | Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY | |
| Phase 3Authorised | not given | Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial | |
| Phase 4Authorised | not given | HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026